Company Profile
Kiniksa Stock Price, News & Catalysts
- Ticker:
- KNSA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
79.18 USD (+3.17%)
Close
Last updated: August 17, 2026
3.61B USD
Market cap
Why the stock is moving
As of Aug 17, 2026, KNSA closed up 3.17% at $79.18. No new same-company headline was identified in the current news window.
Company overview
IL-1 Cardiovascular Franchise
Kiniksa Pharmaceuticals develops and commercializes therapies for diseases with strong biological rationale, with an emphasis on cardiovascular inflammation. Its portfolio is centered on blocking interleukin-1 alpha and beta signaling.
ARCALYST
ARCALYST, or rilonacept, is a weekly subcutaneous IL-1 cytokine trap approved for recurrent pericarditis and selected autoinflammatory disorders. It provides Kiniksa’s commercial foundation in pericarditis.
KPL-387
KPL-387 is an IL-1 receptor 1 monoclonal antibody being developed for recurrent pericarditis. Its target profile is a monthly self-administered injection, and a Phase 2/3 program is assessing dose selection and transition from standard therapy.
KPL-1161
KPL-1161 is an Fc-modified IL-1 receptor antibody in preclinical development. The molecule is designed for quarterly subcutaneous dosing and could extend the franchise toward substantially less frequent administration.
Future catalysts
- Phase 2 dose-focusing data for KPL-387 expected in the second half of 2026.
- Initiation of the Phase 3 pivotal KPL-387 trial expected by year-end 2026.
- Initiation of a Phase 1 trial of KPL-1161 expected by year-end 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Kiniksa (KNSA)?
Kiniksa (KNSA) most recently closed at 79.18 USD, a +3.17% move versus the previous session.
What is the market cap of Kiniksa (KNSA)?
Kiniksa currently has a market capitalization of 3.61B USD on BioPharmSignal.
What does Kiniksa do?
IL-1 Cardiovascular Franchise Kiniksa Pharmaceuticals develops and commercializes therapies for diseases with strong biological rationale, with an emphasis on cardiovascular inflammation. Its portfolio is centered on blocking interleukin-1 alpha and beta signaling. ARCALYST ARCALYST, or rilonacept, is a weekly subcutaneous IL-1 cytokine trap approved for...
On which exchange is KNSA stock listed?
Kiniksa (KNSA) is associated with NASDAQ, United States, Biopharma.
What is IL-1?
IL-1 Cardiovascular Franchise Kiniksa Pharmaceuticals develops and commercializes therapies for diseases with strong biological rationale, with an emphasis on cardiovascular inflammation.
Which conditions is Kiniksa targeting with IL-1?
Kiniksa is associated with inflammatory disease, cardiovascular disease based on its company overview and current catalyst commentary.
How does Kiniksa describe recent progress with IL-1?
Phase 2 dose-focusing data for KPL-387 expected in the second half of 2026. Initiation of the Phase 3 pivotal KPL-387 trial expected by year-end 2026. Initiation of a Phase 1 trial of KPL-1161 expected by year-end 2026.
What is KPL-387?
KPL-387 KPL-387 is an IL-1 receptor 1 monoclonal antibody being developed for recurrent pericarditis.